Stock Report

All about this stock under one free report Last Updated: 05-Sep-2026

Stock Rating

Is this stock worth it? Our ratings reveal the truth.

Wealth Insight New Issue

Serious stock insights. No fluff. No FOMO.

Recently Viewed

Clear All

Sarepta Therapeutics Inc. (DE) (SRPT) Peer Comparison

Stock Card factsheet share-fund-plan-icon

$22.21

up-down-arrow $-0.78 (-3.39%)

As on 04-Sep-2026 13:39EDT

Market cap

info icon

$2,203 Mln

Revenue (TTM)

info icon

$1,974 Mln

P/E Ratio

info icon

--

P/B Ratio

info icon

1.5

Div. Yield

info icon

0 %

Edit peer-selector-edit
Sarepta Therapeutics Inc. (DE) (SRPT) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Madrigal Pharmaceuticals (MDGL)
Market cap ($ Mln)
 2,203 16,765 16,261 13,492 12,332
Revenue ($ Mln)
 1,974 2,782 1,054 2,436 1,284
Net Profit ($ Mln)
 -136.73 491.50 755.85 860.62 -325.10
Net Margin (%)
 -6.93 17.67 71.69 35.33 -25.32
RoE (%)
 -10.25 110.09 -- 42.98 -57.72
Price to Earnings
 -- 35.25 19.00 17.40 --
Price-To-Book
 1.49 39.29 9.76 7.42 23.98

Income Statement ($ Mln)

Sarepta Therapeutics Inc. (DE) (SRPT) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Madrigal Pharmaceuticals (MDGL)
Operating Revenue arrow
1,974.34 2,782.29 1,054.37 2,435.92 1,283.94
Cost of Revenue arrow
818.23 1,982.07 103.47 85.67 109.42
Gross Profit arrow
1,316.73 760.62 588.53 2,236.43 902.26
Operating Expenses arrow
1,299.36 216.81 841.45 1,378.74 1,497.13
Operating Profit (EBIT) arrow
-143.25 583.40 109.45 971.51 -322.62
Other Income arrow
0.00 0.00 0.00 0.00 0.00
Profit before Tax arrow
-130.92 598.92 101.11 1,035.47 -325.10
Provision for Tax arrow
5.81 107.42 -654.74 174.84 0.00
Profit after Tax (Net Income) arrow
-136.73 491.50 755.85 860.62 -325.10
Minority Interest arrow
0.00 0.00 0.00 0.00 0.00
Consolidated Profit arrow
0.00 0.00 0.00 0.00 0.00

Liabilities ($ Mln)

Sarepta Therapeutics Inc. (DE) (SRPT) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Madrigal Pharmaceuticals (MDGL)
Shareholder's Funds arrow
1,527.80 433.86 1,435.90 1,843.76 523.72
Minority Interest arrow
0.00 0.00 0.00 0.00 0.00
Non-Current Liabilities arrow
1,157.81 187.89 384.48 288.55 346.72
Current Liabilities arrow
502.91 1,435.43 464.70 361.93 374.20
Total Liabilities arrow
3,349.70 1,975.47 1,302.02 2,844.42 1,259.59

Assets ($ Mln)

Sarepta Therapeutics Inc. (DE) (SRPT) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Madrigal Pharmaceuticals (MDGL)
Non-Current Assets arrow
964.69 1,006.90 895.24 1,243.41 45.47
Current Assets arrow
2,223.82 1,050.29 1,389.84 1,250.82 1,199.18
Total Assets arrow
3,349.70 1,975.47 1,302.02 2,844.42 1,259.59
Total Debt* arrow
1,045.85 120.10 449.89 165.93 347.75
Net Current Assets arrow
1,720.92 -385.14 0.00 888.90 824.98

Cashflow ($ Mln)

Sarepta Therapeutics Inc. (DE) (SRPT) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Madrigal Pharmaceuticals (MDGL)
Cash From Operating Activities arrow
-205.48 713.22 51.77 884.27 -189.55
Cash Flow from Investing Activities arrow
69.64 -31.14 -8.15 350.44 32.32
Cash from Financing Activities arrow
-168.34 -860.39 34.89 -969.59 255.98
Net Cash Inflow / Outflow arrow
-- -- -- -- --

Ratios

Profitability Ratios

 Sarepta Therapeutics Inc. (DE) (SRPT) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Madrigal Pharmaceuticals (MDGL)
ROCE (%) arrow
-28.25 53.56 -30.01 32.82 -31.49
ROE (%) arrow
-10.25 110.09 163.18 42.98 -57.72
ROA (%) arrow
-3.30 15.64 26.53 29.32 -22.97
EBIT Margin (%) arrow
-3.00 21.13 5.73 31.04 -18.97
Net Margin (%) arrow
-6.93 17.67 71.69 35.33 -25.32
Cash Profit Margin (%) arrow
0.00 0.00 0.00 0.00 0.00

Growth Ratios

 Sarepta Therapeutics Inc. (DE) (SRPT) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Madrigal Pharmaceuticals (MDGL)
Revenue Growth (%) arrow
-20.44 24.67 114.85 9.23 149.04
EBIT Growth (%) arrow
-1,084.14 18.70 136.39 -3.99 9.16
Net Profit Growth (%) arrow
-135.91 17.50 378.76 42.89 -15.32
EPS Growth (%) arrow
-92.45 26.84 353.27 50.42 -0.64
Book Value Growth (%) arrow
13.83 164.02 816.12 -0.70 -42.66

Valuation Ratios

 Sarepta Therapeutics Inc. (DE) (SRPT) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Madrigal Pharmaceuticals (MDGL)
Price / Earnings arrow
-3.16 36.06 -59.76 15.79 -45.32
Price / Book Value arrow
1.98 35.44 -80.42 5.72 21.68
Dividend Yield (%) arrow
-- -- -- -- --
EV/EBITDA arrow
-3.63 28.08 -121.54 12.44 -47.02
Market Cap ($ Cr) arrow
-- -- -- -- --

Solvency Ratios

 Sarepta Therapeutics Inc. (DE) (SRPT) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Madrigal Pharmaceuticals (MDGL)
Debt to Equity arrow
0.55 0.00 0.00 0.00 0.65
Short term debt to equity ratio arrow
0.00 0.00 0.05 0.00 0.00
Current Ratio arrow
4.42 0.73 2.99 3.46 3.20
Quick Ratio arrow
2.62 0.73 2.32 3.38 2.94
Interest Coverage arrow
-1.24 -- 1.62 -- -19.80

Operating Efficiency Ratios

 Sarepta Therapeutics Inc. (DE) (SRPT) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Madrigal Pharmaceuticals (MDGL)
Debtors to sales (%) arrow
24.44 15.88 21.25 13.74 14.98
Asset Turnover arrow
0.48 0.89 0.37 0.83 0.91
Receivable days arrow
97.15 50.42 85.52 43.48 35.88
Inventory Days arrow
344.88 -- 1,056.70 96.17 354.23
Payable days arrow
102.61 6.26 331.01 147.97 300.79
Cash Conversion Cycle arrow
339.42 -- 811.21 -8.32 89.33
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...